Hyperthyroidism Management Guidelines
Initial Evaluation and Diagnosis
When thyrotoxicosis is suspected but not clearly Graves' disease, obtain a radioactive iodine uptake (RAIU) test; add a thyroid scan if nodules are present 1. Confirm biochemical hyperthyroidism with suppressed TSH and elevated free T4 or T3.
Symptomatic Management with Beta-Blockers
Beta-adrenergic blockade should be initiated in elderly patients with symptomatic thyrotoxicosis, anyone with resting heart rate >90 bpm, or those with cardiovascular disease 1. Consider beta-blockers for all symptomatic patients regardless of age 1.
Treatment of Graves' Disease
Three Primary Treatment Options
Methimazole, radioactive iodine (RAI), or thyroidectomy are all acceptable first-line treatments for Graves' hyperthyroidism 1. Choice depends on patient factors, comorbidities, and preferences.
Antithyroid Drug Therapy
Methimazole should be used in virtually every patient choosing antithyroid drug (ATD) therapy, with specific exceptions for first-trimester pregnancy, thyroid storm, and minor methimazole reactions when RAI/surgery are refused 1.
Dosing Strategy:
- Initial dose: 10-20 mg daily for mild-moderate disease; 30-40 mg daily for severe hyperthyroidism or large goiters 1
- Maintenance dose: Typically 5-10 mg daily once euthyroid 1
- Treatment duration: 12-18 months standard; consider long-term therapy (5-10 years) as it reduces recurrence from 50% to 15% 2, 3
Monitoring Requirements:
- Baseline: Complete blood count with differential, liver function tests including bilirubin and transaminases 1
- Patient education: Stop medication immediately and contact physician for rash, jaundice, pale stools, dark urine, joint pain, abdominal pain, nausea, fatigue, fever, or sore throat 1
- Common pitfall: Agranulocytosis and hepatotoxicity require immediate drug cessation
Radioactive Iodine Therapy
Preparation for RAI
Patients at high risk for complications (elderly, severe hyperthyroidism with free T4 2-3× upper limit, cardiovascular disease) require beta-blockade before RAI 1. Consider methimazole pretreatment in these high-risk patients, stopping it 3-7 days before RAI 1, 4.
Dosing and Follow-up
Administer sufficient RAI in a single dose (typically 10-15 mCi) to render the patient hypothyroid 1. This approach prioritizes definitive control over attempting to maintain euthyroidism, which has higher failure rates.
Monitor free T4 and total T3 within 1-2 months post-treatment; if still thyrotoxic, continue monitoring every 4-6 weeks 1. Retreatment with RAI is indicated if hyperthyroidism persists at 6 months or shows minimal response at 3 months 1.
Critical safety measure: Obtain pregnancy test within 48 hours before RAI in all women of childbearing potential 1. RAI is absolutely contraindicated in pregnancy and lactation 1.
Pregnancy-Specific Management
First Trimester
Propylthiouracil (PTU) is the preferred antithyroid drug during the first trimester due to methimazole's association with choanal/esophageal atresia and aplasia cutis 1. Start PTU at 50-150 mg three times daily depending on severity 1.
Second and Third Trimesters
Switch from PTU to methimazole at the beginning of the second trimester (after 16 weeks) due to PTU's risk of potentially fatal hepatotoxicity 1. Use a conversion ratio of approximately 20-30:1 (e.g., 300 mg PTU = 10-15 mg methimazole) 1.
For women already on methimazole who become pregnant: Switch to PTU immediately upon positive pregnancy test, then back to methimazole at second trimester 1.
Treatment Targets in Pregnancy
Maintain maternal free T4 at or slightly above the upper limit of the non-pregnant reference range, keeping TSH suppressed 1. Use the lowest ATD dose necessary to achieve this. Monitor thyroid function monthly and adjust doses accordingly 1.
Critical distinction: Do NOT treat transient hCG-mediated TSH suppression in early pregnancy (gestational thyrotoxicosis/hyperemesis gravidarum) with ATDs unless true Graves' disease is confirmed with elevated free T4 and positive TSH receptor antibodies 1, 5.
TRAb Monitoring
Measure TRAb levels at 22-26 weeks gestation in all pregnant women with current or past Graves' disease to assess fetal/neonatal thyrotoxicosis risk 1. If elevated at diagnosis, remeasure at 22-26 weeks 1.
Surgery During Pregnancy
If thyroidectomy is necessary during pregnancy, perform it in the second trimester 1. First trimester carries teratogenic anesthetic risks and fetal loss; third trimester increases preterm labor risk (4.5-5.5%) 1. Render patient euthyroid with methimazole first, then give potassium iodide in the immediate preoperative period 1.
Surgical Management
Preoperative Preparation
Render patients euthyroid with methimazole before thyroidectomy 1. Administer potassium iodide in the immediate preoperative period to reduce thyroid vascularity 1.
Surgical Approach
Total or near-total thyroidectomy should be performed for Graves' disease 1. Surgery should be done by high-volume thyroid surgeons to minimize complications 1.
Indications Favoring Surgery:
- Large goiters (≥80 g) or symptomatic compression 1
- Suspected or confirmed thyroid malignancy 1
- Pregnancy planned within 4-6 months (before RAI would normalize thyroid function) 1
- Coexisting hyperparathyroidism requiring surgery 1
- Moderate to severe active Graves' ophthalmopathy 1
Subclinical Hyperthyroidism
When TSH is persistently <0.1 mU/L, strongly consider treatment in patients ≥65 years, postmenopausal women not on estrogens/bisphosphonates, those with cardiac risk factors/heart disease/osteoporosis, or symptomatic individuals 1.
When TSH is below normal but >0.1 mU/L, consider treatment in patients ≥65 years or those with cardiac disease/symptoms 1.
Toxic Nodular Goiter Management
Elderly patients and those with cardiovascular disease or severe hyperthyroidism require beta-blockade before RAI therapy 1. Consider methimazole pretreatment in high-risk patients, though this is more controversial than in Graves' disease 1.
Post-Treatment Monitoring
After achieving euthyroidism with any modality, perform lifelong annual thyroid function testing 1. TSH may remain suppressed for over a month after hyperthyroidism resolves, so interpret cautiously alongside free T4 and T3 1.
Key Safety Considerations
Iodine Exposure Before RAI
Avoid iodine-rich foods for at least 1 week before RAI treatment 4. A strict low-iodine diet is unnecessary, but high-iodine sources should be eliminated.
Glucocorticoid Prophylaxis
Administer prophylactic glucocorticoids to patients with mildly active thyroid eye disease before RAI 4. Consider for others at risk of ophthalmopathy worsening.
Lactation
Methimazole is safe during breastfeeding at low doses 1, 6. RAI remains absolutely contraindicated during lactation 1.